FATE
Price
$1.14
Change
+$0.04 (+3.64%)
Updated
Nov 28 closing price
Capitalization
131.5M
91 days until earnings call
Intraday BUY SELL Signals
NUVB
Price
$8.03
Change
+$0.02 (+0.25%)
Updated
Nov 28 closing price
Capitalization
2.75B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs NUVB

Header iconFATE vs NUVB Comparison
Open Charts FATE vs NUVBBanner chart's image
Fate Therapeutics
Price$1.14
Change+$0.04 (+3.64%)
Volume$772.47K
Capitalization131.5M
Nuvation Bio
Price$8.03
Change+$0.02 (+0.25%)
Volume$3.19M
Capitalization2.75B
FATE vs NUVB Comparison Chart in %
FATE
Daily Signal:
Gain/Loss:
NUVB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
FATE vs. NUVB commentary
Dec 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and NUVB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 01, 2025
Stock price -- (FATE: $1.14 vs. NUVB: $8.03)
Brand notoriety: FATE and NUVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 32% vs. NUVB: 34%
Market capitalization -- FATE: $131.5M vs. NUVB: $2.75B
FATE [@Biotechnology] is valued at $131.5M. NUVB’s [@Biotechnology] market capitalization is $2.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileNUVB’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • NUVB’s FA Score: 0 green, 5 red.
According to our system of comparison, both FATE and NUVB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 5 TA indicator(s) are bullish while NUVB’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 5 bullish, 5 bearish.
  • NUVB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both FATE and NUVB are a good buy in the short-term.

Price Growth

FATE (@Biotechnology) experienced а +10.68% price change this week, while NUVB (@Biotechnology) price change was +14.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.92%. For the same industry, the average monthly price growth was +1.16%, and the average quarterly price growth was +72.91%.

Reported Earning Dates

FATE is expected to report earnings on Mar 02, 2026.

NUVB is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+6.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVB($2.75B) has a higher market cap than FATE($132M). NUVB YTD gains are higher at: 201.880 vs. FATE (-30.909). FATE has higher annual earnings (EBITDA): -161.6M vs. NUVB (-201.17M). NUVB has more cash in the bank: 608M vs. FATE (223M). NUVB has less debt than FATE: NUVB (57.8M) vs FATE (81.3M). NUVB has higher revenues than FATE: NUVB (14.4M) vs FATE (8.47M).
FATENUVBFATE / NUVB
Capitalization132M2.75B5%
EBITDA-161.6M-201.17M80%
Gain YTD-30.909201.880-15%
P/E RatioN/AN/A-
Revenue8.47M14.4M59%
Total Cash223M608M37%
Total Debt81.3M57.8M141%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATENUVB
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signal:
Gain/Loss:
NUVB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFDSX20.550.11
+0.54%
Hartford Schroders US MidCap Opps R4
FEGKX16.680.09
+0.54%
Fidelity Equity Growth K6
JHQCX34.720.11
+0.32%
JPMorgan Hedged Equity C
CEMVX14.49-0.04
-0.28%
Causeway Emerging Markets Investor
GVMCX48.91-0.63
-1.27%
Government Street Opportunities

NUVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with FULC. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVB
1D Price
Change %
NUVB100%
+0.25%
FULC - NUVB
46%
Loosely correlated
-3.36%
NRIX - NUVB
43%
Loosely correlated
+2.79%
RCUS - NUVB
42%
Loosely correlated
+2.11%
IPSC - NUVB
41%
Loosely correlated
+0.98%
FATE - NUVB
40%
Loosely correlated
+3.64%
More